A retrospective pharmacovigilance study of post-marketing safety concerns with cefuroxime.

IF 3.4 3区 医学 Q2 PHARMACOLOGY & PHARMACY
Therapeutic Advances in Drug Safety Pub Date : 2024-06-13 eCollection Date: 2024-01-01 DOI:10.1177/20420986241258049
Cheng Jiang, Xiaoxiao Zheng, Ping Li, Jiancheng Qian, Qin Li
{"title":"A retrospective pharmacovigilance study of post-marketing safety concerns with cefuroxime.","authors":"Cheng Jiang, Xiaoxiao Zheng, Ping Li, Jiancheng Qian, Qin Li","doi":"10.1177/20420986241258049","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Cefuroxime has played a crucial role in the prevention and treatment of bacterial infections. However, the differences in adverse events across formulations and routes remain unclear.</p><p><strong>Objectives: </strong>This study aimed to investigate the post-marketing safety of cefuroxime, particularly concerning formulations and routes.</p><p><strong>Design: </strong>A retrospective pharmacovigilance study of cefuroxime was conducted using the data from Food and Drug Administration Adverse Event Reporting System database.</p><p><strong>Methods: </strong>The clinical characteristics and concomitant drugs reported with cefuroxime were investigated. Adverse event signals of cefuroxime were identified based on four disproportionality algorithms. The signal differences of cefuroxime across formulations and routes were further examined.</p><p><strong>Results: </strong>A total of 1810 adverse event reports associated with cefuroxime were identified, and 181 cefuroxime-associated signals were detected. Compared with tablets, injections were more likely to cause preferred terms 'blood pressure decreased' and 'anaphylactic shock'. In addition, system organ class 'eye disorders' significantly increased when cefuroxime was administered intraocularly, underscoring the importance of exercising caution regarding ocular toxicity.</p><p><strong>Conclusion: </strong>The adverse events associated with cefuroxime were significantly different across formulations and routes, which deserve special attention in clinical use.</p>","PeriodicalId":23012,"journal":{"name":"Therapeutic Advances in Drug Safety","volume":null,"pages":null},"PeriodicalIF":3.4000,"publicationDate":"2024-06-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11177735/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Therapeutic Advances in Drug Safety","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/20420986241258049","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Cefuroxime has played a crucial role in the prevention and treatment of bacterial infections. However, the differences in adverse events across formulations and routes remain unclear.

Objectives: This study aimed to investigate the post-marketing safety of cefuroxime, particularly concerning formulations and routes.

Design: A retrospective pharmacovigilance study of cefuroxime was conducted using the data from Food and Drug Administration Adverse Event Reporting System database.

Methods: The clinical characteristics and concomitant drugs reported with cefuroxime were investigated. Adverse event signals of cefuroxime were identified based on four disproportionality algorithms. The signal differences of cefuroxime across formulations and routes were further examined.

Results: A total of 1810 adverse event reports associated with cefuroxime were identified, and 181 cefuroxime-associated signals were detected. Compared with tablets, injections were more likely to cause preferred terms 'blood pressure decreased' and 'anaphylactic shock'. In addition, system organ class 'eye disorders' significantly increased when cefuroxime was administered intraocularly, underscoring the importance of exercising caution regarding ocular toxicity.

Conclusion: The adverse events associated with cefuroxime were significantly different across formulations and routes, which deserve special attention in clinical use.

关于头孢呋辛上市后安全问题的回顾性药物警戒研究。
背景:头孢呋辛在预防和治疗细菌感染方面发挥了重要作用。然而,不同剂型和途径的不良反应差异仍不清楚:本研究旨在调查头孢呋辛上市后的安全性,尤其是与制剂和途径有关的安全性:设计:利用食品药品管理局不良事件报告系统数据库中的数据,对头孢呋辛进行回顾性药物警戒研究:方法:调查了头孢呋辛的临床特征和报告的伴随药物。根据四种比例失调算法确定了头孢呋辛的不良事件信号。进一步研究了头孢呋辛在不同剂型和途径中的信号差异:结果:共确定了 1810 份与头孢呋辛相关的不良事件报告,发现了 181 个与头孢呋辛相关的信号。与片剂相比,注射剂更容易引起首选术语 "血压下降 "和 "过敏性休克"。此外,在眼内注射头孢呋辛时,系统器官类 "眼部疾病 "显著增加,这强调了谨慎对待眼部毒性的重要性:与头孢呋辛相关的不良事件在不同制剂和途径中存在明显差异,在临床使用中值得特别注意。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Therapeutic Advances in Drug Safety
Therapeutic Advances in Drug Safety Medicine-Pharmacology (medical)
CiteScore
6.70
自引率
4.50%
发文量
31
审稿时长
9 weeks
期刊介绍: Therapeutic Advances in Drug Safety delivers the highest quality peer-reviewed articles, reviews, and scholarly comment on pioneering efforts and innovative studies pertaining to the safe use of drugs in patients. The journal has a strong clinical and pharmacological focus and is aimed at clinicians and researchers in drug safety, providing a forum in print and online for publishing the highest quality articles in this area. The editors welcome articles of current interest on research across all areas of drug safety, including therapeutic drug monitoring, pharmacoepidemiology, adverse drug reactions, drug interactions, pharmacokinetics, pharmacovigilance, medication/prescribing errors, risk management, ethics and regulation.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信